renal disease – Page 4 – Communicable Diseases Research

A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort

유효한 경고 또는 임상 지식: 다기관 일치 코호트에서 손상된 신장 기능이 있는 환자에서 렘데시비르의 안전성 결과 평가

Comparative Study

Published on 2021-01-202022-09-11
Journal: Antimicrobial Agents and Chemotherapy [Category] 치료제,

Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial

COVID-19 폐렴 환자에서 호흡 악화 예방을 위한 BIO101의 효능 및 안전성 테스트(COVA 연구): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-112022-09-10
Journal: Trials [Category] 임상,

[키워드] 1:1 20-hydroxyecdysone absence accumulation ACE2 Activation acute respiratory distress acute respiratory distress syndrome adaptive addition administration Airway Pressure all-cause mortality ALT Alter amenorrhea Analysis angiotensin angiotensin converting enzyme angiotensin converting enzyme 2 Angiotensin converting enzyme-2 Anti-inflammatory anticipated approved ARDS arterial oxygen saturation AST Asymptomatic balance baseline being Belgium beneficiary Bilirubin BIO101 Biomarker Biomarkers birth control blinded Brazil breath Cardiomyopathy Care Caregivers caused clinical development Clinical finding Clinical findings clinical picture co-morbidities co-morbidity collected Compliance condition condom conducted confirmation Consumption Continuous Continuous Positive Airway Pressure Contraception contraceptive method coronavirus disease COVID-19 COVID-19 infection COVID-19 infection symptom COVID-19 infection symptoms COVID-19 patient COVID-19 patients criteria criterion daily dose Day death defined Department Deterioration develop diabetes diagnosis of COVID-19 dialysis discharge discharged disease dissemination DMC dose double-blind downstream ECMO Effect effective Efficacy Efficacy and safety EGFR element eligible participant Eligible participants endotracheal tube Endpoint enzyme etonogestrel EudraCT European evaluate event Evidence evidence of exclusion criteria expected exploratory extracorporeal membrane oxygenation female female participants Final FiO2 Flow following form France French functional Gault Gender healthcare healthcare facility heart disease High-flow oxygen higher risk hospital hospital care Hospitalization Hospitalized hypersensitivity hypertension IBM ICF Imbalance include Inclusion independent indication Infection Inflammation informed consent form injection Interim analyses interim analysis Intervention intrauterine device Intubated Invasive mechanical ventilation IWRS system lactating limit Liver function liver function tests male participants marker Mas receptor maximum measure mechanical ventilation medical intervention medication medications minute moderate morbidities Moribund Mortality mouth Multiorgan dysfunction muscles myocarditis negative urine pregnancy test Non-COVID-19 number obesity objective observation offer Older oral contraceptive outcome outlined oxygen Part participant partner pathway Pathways patients with COVID-19 patients with SARS-CoV-2 PCR performed Pericarditis Physical examination Placebo placebo-controlled Pneumonia positive airway pressure post-intervention post-menopausal powder pregnancy test pressure primary endpoint proof proportion Proportion of participant protocol public health randomised randomised controlled trial randomization RAS reached receive receiving receptor recruited recruitment Registered renal renal disease renal insufficiency Renin renin angiotensin system renin-angiotensin system reproduction required resource respiratory Respiratory distress syndrome Respiratory failure Respiratory function respiratory symptoms restored risk Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV2 SARS-CoV2 spike protein second secondary secondary endpoint security severe pneumonia Shock Social Security specimen Sperm Spike protein SpO2 Statistical power status Sterilization Stratification stratified study medication Study protocol supplementary material survival suspicion Symptom syndrome tachypnea target population tested Testing the primary endpoint therapeutic therapeutic option tissue Tolerability Total total bilirubin Treatment treatment arm treatment period Triage Trial Trial registration ULN Urine USA variety vasectomy Version Viral load water website
[DOI] 10.1186/s13063-020-04998-5 PMC 바로가기 [Article Type] Letter

Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)

입원한 COVID-19 환자의 중증 SARS-CoV-2 감염 예방을 위한 재조합 인간 C1 에스테라제 억제제(conestat alfa): 무작위, 병렬 그룹, 공개 라벨, 다중 센터에 대한 연구 프로토콜의 구조화된 요약 파일럿 시험(PROTECT-COVID-19)

Letter

Published on 2021-01-042022-09-10
Journal: Trials [Category] 임상,

[키워드] 24 hour 24 hours Activation activities acute lung injury addition adjusted Administered administration allergy Antibiotics anticipated anticoagulation arterial Arterial hypertension Basel Blinding BMI Brazil Breast Breast feeding breathing ambient air C-reactive protein C1 esterase inhibitor cardiovascular disease Caregivers changes in Chest Child-Pugh score chronic chronic pulmonary disease chronic renal disease cirrhosis class clinical Clinical improvement clinical trial comparator comparator Patients complement complement system completion conducted Conestat alfa Contact contact activation system contraindication control group Corticosteroids COVID-19 COVID-19 patient CT scan death defined discharge disease disease severity dissemination drug Duration Efficacy and safety element eligibility enrolment evidence of experimental arm family members FIVE followed by history hospital Hospitalization hospitalized patient hypertension ICU IL-6 inhibitor IL-6R improvement Incapacity include inclusion criteria individual Infection inflammatory cascade inflammatory cascades inflammatory proteins inhibitor Interactive Web Response System interim analysis Intravenous injection invasive invasive or non-invasive ventilation investigator-initiated investigators kallikrein kinin system laboratory parameter Liver cirrhosis Local Lung injury mechanical ventilation non-invasive ventilation not blinded number obesity objective Open-label open-label trial Ordinal Scale outcome outcome assessor outcome assessors oxygen oxygen saturation pandemic PaO parallel-group participant Participants Participation Patient performed Pregnancy primary endpoint progression proportion protocol pulmonary disease pulmonary involvement randomised randomization Randomized randomized trial receive recombinant recruited recruitment Registered Remdesivir renal renal disease required risk factor Sample size SARS-COV-2 infection SARS-CoV-2 pandemic scale screened secondary Secondary outcomes severe COVID-19 severe SARS-CoV-2 Standard of care status Study protocol subject supplemental oxygen supplementary material suspicion Switzerland Symptom the SARS-CoV-2 the WHO their family members Tocilizumab Treatment treatment arm Trial Two interim analyses Two interim analysis virological clearance website WHO WHO ordinal scale with COVID-19 X-ray
[DOI] 10.1186/s13063-020-04976-x PMC 바로가기 [Article Type] Letter

Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: A structured summary of a study protocol for an open-label randomized clinical trial

비인두에서 COVID-19에 대한 포비돈 요오드의 바이러스 살균 효과: 공개 라벨 무작위 임상 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-042022-09-10
Journal: Trials [Category] 임상,

[키워드] 6 hour 6 hours acute renal failure adverse effect adverse effects adverse event adverse events anticipated Arm-1 ARMS assigned baseline being randomized Blinding both groups chronic renal failure clinical trial college comparator Concentration conducted confirmed case COVID-19 COVID-19 case COVID-19 virus creatinine criteria Data analysis diagnosed diet disease dissemination distilled water DMC Efficacy element eligibility assessment estimated glomerular filtration rate evaluate exclusion filtration rate Final glomerular filtration rate groups Identifier in both groups include Inclusion inclusion criteria independent Informed consent Intervention intervention arm intervention arms intervention group invasive involved Iodine KDIGO lactating masking Microsoft Excel Modification nasal Nasal Irrigation Nasal spray nasopharynx Noninvasive ventilation number objective Occurrence Open-label Other outcome parallel-group participant Patient performed Placebo positive Povidone Iodine pregnant women Primary outcome proportion protocol random number generation randomization Randomized randomized clinical trial RCT receive recruited Registered renal renal disease renal failure required routine care Sample size screened sealed secondary outcome sensitivity Seven single-center Stage statistician status Study protocol supplementary material Symptom Thyroid thyroid disease Trial trial protocol Trial registration Version virucidal virus website
[DOI] 10.1186/s13063-020-04963-2 PMC 바로가기 [Article Type] Letter

COVID-19 Antibodies and Outcomes among Outpatient Maintenance Hemodialysis Patients

외래 유지 혈액 투석 환자의 COVID-19 항체 및 결과

Article

Published on 2020-12-092022-09-11
Journal: Kidney360 [Category] SARS, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibodies antibody Aside Asymptomatic asymptomatic infection Black race Clustering COPD coronavirus COVID-19 COVID-19 antibody COVID-19 infection dialysis End stage renal disease Hemodialysis Hispanic ethnicity hospital hospital mortality rate Hospitalization Hospitalized Immunocompromised Immunocompromised patient Immunocompromised patients implication Infection maintenance Maintenance hemodialysis Mortality mortality rates nasopharyngeal New York occur other variable Outpatient outpatients Patient patients PCR positive PCR positivity positive PCR result Prevalence prevalent public health renal renal disease respiratory reverse-transcriptase PCR risk factor RT-PCR SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 positivity Seroconversion serologic testing seropositive Seropositivity Seroprevalence severe acute respiratory syndrome Coronavirus significant difference significant differences significantly taxis tested the patient
[DOI] 10.34067/KID.0006292020 PMC 바로가기 [Article Type] Article

Study protocol for resolution of organ injury in acute pancreatitis (RESORP): an observational prospective cohort study

급성 췌장염(RESORP)의 장기 손상 해결을 위한 연구 프로토콜: 관찰 전향적 코호트 연구

Observational Study

Published on 2020-12-072022-09-10
Journal: BMJ Open [Category] Fulltext, MERS, SARS, 임상, 치료기술,

[키워드] acute pancreatitis adult intensive & critical care Analysis assessment biochemical Cancer cardiopulmonary exercise testing cardiovascular Caregivers cellular senescence Clinical research cognitive Cognitive function Cohort diabetes Diabetes Mellitus disease dissemination echocardiography episode episode of Ethics ethics committee explain Follow-up Gastrointestinal general diabetes General population hospital incidence individual IRAS life liver mechanism MRI number organ organ dysfunction organ injury organ system outcome measure pancreatic disease participant Patient physiological predictor Premature primary outcome measure prospective cohort study protocol Pulmonary function testing Quality Quality of life receiving recruitment registration numbers registry renal renal disease Research Research Ethics researchers respiratory Result secondary secondary outcome measures severity survival Survivors undergo university university hospital
[DOI] 10.1136/bmjopen-2020-040200 PMC 바로가기 [Article Type] Observational Study

Characteristics and outcomes of hospitalised patients with acute kidney injury and COVID-19

급성신장손상 및 코로나19로 입원한 환자의 특징 및 결과

Research Article

Published on 2020-11-032022-08-13
Journal: PLoS ONE [Category] Biochemistry, COVID-19, MERS,

[키워드] Acute kidney injury Admission Adult patients AKI association baseline characteristics Biochemistry Comorbidities COVID-19 Critical care death Deprivation Deterioration diagnosis of COVID-19 disease Escalation foundation hospital hospitalised patient Initially laboratory data mechanical ventilation medications Mortality multiple organ involvement observations outcome overall mortality P-value pandemic Patient patients patients with AKI patients with COVID-19 presenting Prevent Record renal renal disease renal function renal replacement therapy replacement therapy required respiratory Result retrospective retrospective review risk shown Spread the disease Trust university with COVID-19 World Health Organisation
[DOI] 10.1371/journal.pone.0241544 PMC 바로가기 [Article Type] Research Article

The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial

입원한 COVID-19 환자의 결과 개선에 대한 파모티딘의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-10-132022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] Alanine Alanine transaminase alcoholism All participant All participants allergies allergy allocation approved ARMS aspartate Aspartate transaminase assigned assumption Bandar Abba Bandar Abbas baseline Blinding block randomization blood count Care Chronic kidney disease clearance clinical clinical trial clinical trials code Committee company comparator Comparator group complete blood count concealed control group control groups COVID-19 COVID-19 patient COVID-19 patients creatinine creatinine clearance criteria Dasatinib dialysis discharge dissemination dosage drug therapy electrocardiogram element eligibility criteria End-stage renal disease ethics committee Evidence evidence of excluded expected Famotidine G6PD Glucose Glucose 6 phosphate grouping groups Hepatitis hepatitis C Hospitalized Immunocompromised Immunocompromised patients Infection Intervention Kidney disease Lactate lactate dehydrogenase lead limit Liver disease Local lung infiltration maximum Medical Science Medical Sciences moderate need for dialysis Neratinib normal limit number objective online tool oral contraceptives outcome outcome assessor outcome assessors oxygen oxygen saturation Ozanimod participant Patient patients patients with COVID-19 Pazopanib PCR test pharmaceutical Pharmaceutical Company phosphate Placebo placebo-controlled porphyria positive Pregnancy protocol psoriasis random randomisation randomised randomised controlled trial randomized clinical trial Randomly randomly divided receive recruitment Registered registry renal renal disease renal failure reported Research question researcher respiration rate responsible Rilpivirine Sample size sample size calculation sequence sequence information single-blind Siponimod Standard study drug Study protocol subject submitted technology temperature the ethics committee therapy title Tizanidine transaminase Treatment treatment group Treatment protocol treatment protocols Trial registration two group two groups university Version website were measured written consent
[DOI] 10.1186/s13063-020-04773-6 PMC 바로가기 [Article Type] Letter

Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis

미국의 COVID-19 성인 31,461명의 사망률과 관련된 동반 질환: 연합 전자 의료 기록 분석

Research Article

Published on 2020-09-102022-08-13
Journal: PLoS Medicine [Category] COVID-19, Medicine and Health Sciences, SARS,

[키워드] 95% CI 95% confidence interval African American age analyses Analysis Asian association Bame Characteristics Charlson Comorbidity Index chronic pulmonary disease clinical trial clinical trials coded collected Comorbidities Comorbidity condition conducted congestive heart failure coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patients data entry database death Dementia determine develop diabetes Diabetes Mellitus disease Electronic health records electronic medical record electronic medical records Ethnicity Evidence example Factor female group groups health condition healthcare help higher odd higher odds hospital Hypothesis identify identifying include interquartile range Intervention likelihood limitation Liver disease Logistic regression male Male sex median age medical record medical records Mild Mortality multivariate Myocardial infarction network Odds ratio Older Older age organization outbreak participant Participants Patient patients people with COVID-19 previous study provided public health emergency remained renal renal disease reported Research researcher Result retrospective cohort study risk of death Sex significantly solid tumor Stephanie stratified study period suggested the United State Tumor United States white with COVID-19
[DOI] 10.1371/journal.pmed.1003321 PMC 바로가기 [Article Type] Research Article

High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial

COVID-19에 따른 급성 호흡곤란 증후군에 대한 고용량 덱사메타손 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-08-262022-08-13
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 active cancer acute respiratory distress acute respiratory distress syndrome Adult patients advance directives Advanced cancer age alpha error anticipated approved ARDS assessment assigned bilateral pulmonary infiltrates Blinding block breast-feeding Buenos Aires capture cardiac disease CEMIC clinical clinical trial code Complete concealed Confirmed COVID-19 COVID-19, Dexamethasone, Acute Respiratory Distress Syndrome, Randomised controlled trial, protocol, Steroids delirium develop Dexamethasone diagnosis of SARS-CoV-2 directive discharge disease dissemination do not resuscitate dose Effectiveness element End-Expiratory Pressure evaluate exclusion criteria Expiratory Pressure explained failure followed by Frequency glucocorticoid Glucocorticoids group hemodynamic High dose HIV infection hypoxemic Hypoxemic respiratory failure ICU Immunosuppression Immunosuppressive agents include inclusion criteria Infection Informed consent intensive care unit International legal guardian Length less Life expectancy local Ethics Committee mechanical ventilation Mortality multicenter muscle weakness Nosocomial infection Nosocomial infections number objective open open label open trial other disease other diseases outcome Palliative care PaO parallel group participant Participation Patient Patient care platform Pneumonia Positive end-expiratory pressure power power of 80% Prednisone pressure Prone position protocol R language random randomised randomised controlled trial randomization Randomized randomized clinical trial receive recruitment Registered renal renal disease respiratory respiratory distress Respiratory distress syndrome Respiratory failure resuscitate order RT-PCR Sample size SARS-COV-2 infection SARS-CoV-2 pneumonia secondary Secondary outcomes secondary to sequence Sequential Organ Failure Assessment severe immunosuppression SOFA Standard deviation status Stratified randomization Study protocol subject Support syndrome table terminal Terminal disease title Treatment treatment groups Trial Trial registration two-tailed alpha error Variation ventilator ventilator-free day Ventilator-free days ventilatory Version viral shedding weakness website women
[DOI] 10.1186/s13063-020-04646-y PMC 바로가기 [Article Type] Letter